News & Views
Role Focused on Developing US Business
Aug 04 2020
Dr Paul Overton has joined Sygnature Discovery as Senior VP of Business Development, focusing primarily on expanding the North American market for the drug discovery and pre-clinical solutions provider. In this newly created role, he will work alongside Dr Paul Clewlow, Senior VP, Business Development and Executive Board Director.
Dr Overton has more than 20 years’ experience in business development roles within the CRO sector. He joins Sygnature from the Global testing specialist Eurofins, where he was Head of European Sales, Marketing and Key Account Management. His previous employers include Evotec and Aptuit where he was Global Head of Business Development and Marketing. He has a biological sciences background with a PhD in cell biology obtained from the University of Surrey. After several years working in various research laboratories, he made the move into business development.
Speaking of his new role at Sygnature Dr Overton said: ‘This is an exciting, dynamic and fast-growing science-driven company. I am really looking forward to building stronger relationships with existing US customers and creating further strategic partnerships with major pharmaceutical and biotech companies.”
Dr Clewlow added: More than half of our business is currently in the US, with a mixture of big pharma and VC-backed biotech clients,’ he says. ‘I have known Paul for a number of years and his experience in business development and drug discovery will be invaluable in accelerating our business growth there. He will also make a significant contribution to our global sales and marketing strategy.”
In This Edition Articles - Deep characterisation and quantitative analysis - Seamless HPLC Method Transfer - How does a sample’s adventure unfold at Diamond? Mass Spectrometry & Spectr...
View all digital editions
Aug 10 2021 Pennsylvania, PA, USA & Online
Aug 18 2021 Beijing, China
Aug 22 2021 Xi'an, China
Aug 22 2021 Atlanta, GA, USA & Virtual
Aug 22 2021 Digital event